Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shared his thoughts on the most important recent advances in non–small cell lung cancer (NSCLC), including a better understanding of patients who may benefit from immunotherapy.
Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shared his thoughts on the most important recent advances in non–small cell lung cancer (NSCLC), including a better understanding of patients who may benefit from immunotherapy.
Transcript
What are some notable recent advancements in the NSCLC treatment landscape?
I think the most important recent advances have been the continuation of understanding that non–small cell lung cancer is a group of very heterogeneous patients and diseases and that certainly, we've transitioned from 20 or 30 years ago, [when it was] kind of one-size-fits-all, to realizing that there are a number of biomarker findings that are important in deciding which treatment approach is best for the individual patient that that's in front of you. We know that genomic comprehensive testing at the time of diagnosis is important. Certainly, in those patients with actionable genomic alterations, the best first line treatment is targeted therapies.
We also know that we're beginning to understand who the patients that get greater benefit from immunotherapy [are], versus those patients that probably need a new idea from an immunotherapeutic point of view. With this better understanding of the underlying biology of non–small cell lung cancer, it's really created a number of new therapeutic options. In addition to the targeted agents that are there, we have validated the PD-1 and PD-L1 pathway, we've also validated the CTLA-4 pathway as a target of anti-cancer therapy.
In the targeted therapy space, I think we're on the verge of understanding patterns of resistance. We have some pretty good drugs to use in the first line, but the issue there is that most patients develop resistance. And so, we're beginning to understand a little bit about what those resistance mechanisms are, and then developing strategies that address how patients get around those very active first line drugs.
It's an exciting time in non–small cell lung cancer, but I think the important advances are understanding the underlying biology of each individual patient, which obviously there's a lot of overlap, but there's a lot of opportunity to personalize therapy as best we can. And I hope that we will continue along the lines that we've seen over the past 5 to 10 years.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More